Title: Pardoprunox as adjunct therapy to levodopa in patients with Parkinson's disease experiencing motor fluctuations: results of a double-blind, randomized, placebo-controlled, trial.
Journal: Parkinsonism & related disorders 20120501
Title: Temporal stability of the Unified Dyskinesia Rating Scale.
Journal: Movement disorders : official journal of the Movement Disorder Society 20111201
Title: In vivo effects of pardoprunox (SLV308), a partial D₂/D₃ receptor and 5-HT1A receptor agonist, on rat dopamine and serotonin neuronal activity.
Journal: Synapse (New York, N.Y.) 20111001
Title: Identification of N-propylnoraporphin-11-yl 5-(1,2-dithiolan-3-yl)pentanoate as a new anti-Parkinson's agent possessing a dopamine D2 and serotonin 5-HT1A dual-agonist profile.
Journal: Journal of medicinal chemistry 20110714
Title: Pardoprunox in early Parkinson's disease: results from 2 large, randomized double-blind trials.
Journal: Movement disorders : official journal of the Movement Disorder Society 20110701
Title: The partial dopamine agonist pardoprunox (SLV308) administered in combination with l-dopa improves efficacy and decreases dyskinesia in MPTP treated common marmosets.
Journal: Experimental neurology 20101201
Title: Pardoprunox reverses motor deficits but induces only mild dyskinesia in MPTP-treated common marmosets.
Journal: Movement disorders : official journal of the Movement Disorder Society 20101015
Title: An in vivo pharmacological evaluation of pardoprunox (SLV308)--a novel combined dopamine D(2)/D(3) receptor partial agonist and 5-HT(1A) receptor agonist with efficacy in experimental models of Parkinson's disease.
Journal: European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology 20100801
Title: Double-blind study of pardoprunox, a new partial dopamine agonist, in early Parkinson's disease.
Journal: Movement disorders : official journal of the Movement Disorder Society 20100430
Title: Safety and tolerability of pardoprunox, a new partial dopamine agonist, in a randomized, controlled study of patients with advanced Parkinson's disease.
Journal: European neurology 20090101
Title: In vitro characterization of SLV308 (7-[4-methyl-1-piperazinyl]-2(3H)-benzoxazolone, monohydrochloride): a novel partial dopamine D2 and D3 receptor agonist and serotonin 5-HT1A receptor agonist.
Journal: Synapse (New York, N.Y.) 20061215
Title: SLV-308. Solvay.
Journal: Current opinion in investigational drugs (London, England : 2000) 20030701
Title: Glennon JC, et al. In vitro characterization of SLV308 (7--methyl-1-piperazinyl-2(3H)-benzoxazolone, monohydrochloride): a novel partial dopamine D2 and D3 receptor agonist and serotonin 5-HT1A receptor agonist. Synapse. 2006 Dec 15;60(8):599-608.
Title: Jones CA, et al. An in vivo pharmacological evaluation of pardoprunox (SLV308)--a novel combined dopamine D(2)/D(3) receptor partial agonist and 5-HT(1A) receptor agonist with efficacy in experimental models of Parkinson's disease. Eur Neuropsychopharmacol. 2010 Aug;20(8):582-593.
